2026-03-13
Scandinavian Biopharma AB
ETVAX Gains Attention as Hope Rises Against Childhood Diarrhoea scandinavianbiopharma.se ↗
2026-02-20
Scandinavian Biopharma AB
Scandinavian Biopharma Announces Publication of ETVAX® Phase 2b Data in The Lancet Infectious Diseases and Confirms Phase 3 Readiness scandinavianbiopharma.se ↗
2024-10-02
Scandinavian Biopharma AB
Scandinavian Biopharma Announces Successful Completion of Pediatric Phase IIb Trial for ETVAX® Vaccine in The Gambia scandinavianbiopharma.se ↗
2022-12-05
Scandinavian Biopharma AB
New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines scandinavianbiopharma.se ↗
2021-09-28
Scandinavian Biopharma AB
New ETVAX® data will be presented during VASE, a conference designed to spark innovation and accelerate the momentum for research and development on enteric vaccines scandinavianbiopharma.se ↗
2020-10-09
Scandinavian Biopharma AB
Scandinavian Biopharma enters into Agreement with USAMRAA to facilitate the development of the oral vaccine ETVAX® against travellers’ diarrhoea scandinavianbiopharma.se ↗
2020-05-26
Scandinavian Biopharma AB
Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa scandinavianbiopharma.se ↗
2020-02-20
Scandinavian Biopharma AB
Scandinavian Biopharma secures €10.6 million from EDCTP for a Phase III trial of ETVAX® in children in low- and middle-income countries scandinavianbiopharma.se ↗
2019-11-20
Scandinavian Biopharma AB
Scandinavian Biopharma reports successful results of the oral, inactivated ETEC vaccine candidate ETVAX® against enterotoxigenic E. coli diarrhoea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh scandinavianbiopharma.se ↗
2019-10-16
Scandinavian Biopharma AB
The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland scandinavianbiopharma.se ↗
2019-05-14
Scandinavian Biopharma AB
Scandinavian Biopharma announces great progress in the development of ETVAX® as well as a strong organic growth for the distribution business scandinavianbiopharma.se ↗
2019-04-30
Scandinavian Biopharma AB
Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin scandinavianbiopharma.se ↗
2019-01-23
Scandinavian Biopharma AB
Scandinavian Biopharma has been awarded 7.4 million EUR from the EU for clinical trials of ETVAX® – a unique and newly developed vaccine against diarrheal disease scandinavianbiopharma.se ↗
2018-06-11
Scandinavian Biopharma AB
New ETVAX® data will be presented during Vaccines Against Shigella and ETEC (VASE) conference in Mexico scandinavianbiopharma.se ↗
2017-10-04
Scandinavian Biopharma AB
New ETVAX® data will be presented during Vaccines for Enteric Diseases (VED) conference scandinavianbiopharma.se ↗
2016-07-05
Scandinavian Biopharma AB
Etvax® was presented at VASE Conference scandinavianbiopharma.se ↗
2015-11-01
Scandinavian Biopharma AB
ETVAX® was presented at ASTMH in Philadelphia scandinavianbiopharma.se ↗
2015-06-05
Scandinavian Biopharma AB
ETVAX® was presented as the lead candidate at CISTM14 scandinavianbiopharma.se ↗
2014-06-19
Scandinavian Biopharma AB
Etvax® is now a registered trademark scandinavianbiopharma.se ↗
2013-02-07
Scandinavian Biopharma AB
Scandinavian Biopharma through its subsidiary ETVAX continues clinical development scandinavianbiopharma.se ↗
Show 8 more releases